Human genetics leading the pull of investors into neuro
Human genetics and new modalities converge to lower the risk for neurology start-ups
Human genetics and new modalities converge to lower the risk for neurology start-ups.
The stain of “too high-risk for investment” that plagued neuroscience for years has now worn off, according to a BioCentury analysis of early stage venture investments. Neurology sits second only to cancer for seed and series A funds raised, close to or exceeding $1 billion in each of the last three years.
Rooting therapeutic approaches in human biology, especially genetics, is the primary method for mitigating risk, and the strategy is dictating much of where the money goes.
According to BioCentury’s BCIQ database, neuroscience has ranked second out of 19 therapeutic areas in all but one of the last seven years, behind cancer and ahead of traditionally “hot” areas such as autoimmunity and inflammation.